Generics in Canada: The race for market exclusivity

The Supreme Court of Canada has tentatively set April 20, 2015 as the date for the hearing of Sanofi’s appeal against a court’s decision that the company is liable for generic drug maker Apotex’s lost sales of ramipril based on section 8 of the Patented Medicines (Notice of Compliance) Regulations (NOC Regulations).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

10 July 2026 Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.

Americas

Exelixis opens two-front patent dispute over Cabometyx copies

9 July 2026 Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.

Americas

LSD trade secrets suit over clinical trail info thrown out by judge

2 July 2026 A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.

More features

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

Exelixis opens two-front patent dispute over Cabometyx copies

BioNTech and Pfizer secure big European win over mRNA patent

Influential Women in IP 2026: Who made the list?

UPC revives patent, but timing sinks Guardant’s appeal

LSD trade secrets suit over clinical trail info thrown out by judge

HGF expands European offering with pair of in-house hires

Vinson & Elkins grows West Coast patent and trade secrets bench

Generics in Canada: The race for market exclusivity

More on this story

Editor's picks

Editor's picks

More features